Recession-Proof Value Stock: 1 Pharma Stock to Buy Today

Aeterna Zentaris Inc. (TSX:AEZS)(NASDAQ:AEZS) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests.

| More on:

Aeterna Zentaris (TSX:AEZS)(NASDAQ:AEZS) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company’s lead product, Macimorelin, is the first and only United States (U.S.) Food and Drug Administration (FDA) and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Macimorelin is currently marketed in the U.S. under the tradename Macrile through a licence agreement with Novo Nordisk (NYSE:NVO), where Aeterna receives royalties on net sales. According to a commercialization and supply agreement, the company plans to seek regulatory approvals and then commercialize Macimorelin in Israel.

Lucrative royalties

Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that Macimorelin will be marketed in Europe and the United Kingdom through a licence agreement with Consilient Health, and Aeterna will receive royalties on net sales and other potential payments. The company is also leveraging the clinical success and compelling safety profile of Macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency, an area of significant unmet need.

Diverse revenue base

The company is actively pursuing business development opportunities for the commercialization of Macimorelin in Asia and the rest of the world, in addition to other non-strategic assets to monetize value. Aeterna’s total revenue for the 12-month period ended December 31, 2020, was $3.7 million as compared with $0.5 million for the same period in 2019, representing an increase of $3.2 million.

The 2020 revenue was comprised of $2.4 million in product sales, $0.9 million in licensing revenue, $0.3 million in supply chain and $0.07 million in royalty income. In 2020, all revenue was earned from Novo Nordisk.

Development of a vaccine against COVID-19

On February 2, 2021, the company announced that it had entered an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at a university. The vaccine technology developed uses the typhoid fever vaccine, Salmonella Typhi, as a carrier strain and has the potential to be an orally active vaccine against infection with SARS-CoV-2 and development of COVID-19.

Under the option agreement with the university, Aeterna has the right to negotiate an exclusive worldwide licence to develop technology for the prevention of coronavirus diseases, including COVID-19. Management believe that, if it is determined that there is sufficient data to advance into human clinical trials, the development program for this particular COVID-19 vaccine is expected to be abbreviated, because clinical safety data and manufacturing technology is already available for the underlying vaccine strain.

Leveraging platform technology

On March 14, 2021, the company exercised the option in the option agreement and entered a licence agreement with a university. Pursuant to the terms of the university licence agreement, the company has been granted an exclusive, world-wide, licence to certain patents and know-how owned by the university to research, develop, manufacture, and sell a potential COVID-19 vaccine using the university’s bacterial vaccine platform technology.

Recently, the company also announced that it had licensed the exclusive worldwide rights to develop, manufacture, and commercialize targeted, highly specific, autoimmunity modifying proteins, currently in early preclinical development, for the potential treatment of spectrum disorder. This could significantly enhance shareholder value.

Should you invest $1,000 in Computer Modelling Group Ltd. right now?

Before you buy stock in Computer Modelling Group Ltd., consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Computer Modelling Group Ltd. wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,345.77!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*.

See the Top Stocks * Returns as of 4/21/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Tech Stocks

Income and growth financial chart
Tech Stocks

2 Canadian Stocks That Could Turn $10,000 Into $100,000

If you're looking for growth and income, these two are some of the best options out there.

Read more »

money goes up and down in balance
Tech Stocks

1 Magnificent Tech Stock Down 27% to Buy and Hold Forever

Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) is starting to look severely undervalued after its latest drop!

Read more »

ways to boost income
Tech Stocks

1 Undervalued TSX Stock Down 18% to Buy and Hold

This TSX stock remains down but is due for a huge comeback for investors.

Read more »

grow money, wealth build
Tech Stocks

This TSX Stock Down 20% Could Triple Your Money by 2028

Down 20% from its 52-week high, this TSX stock is positioned to more than triple investor returns over the next…

Read more »

money goes up and down in balance
Tech Stocks

The Smartest Canadian Stock to Buy With $600 Right Now

The Canadian stock market has some big winners trading at discounted share prices, ripe for the taking, and here’s one…

Read more »

Muscles Drawn On Black board
Dividend Stocks

The Best Canadian Stocks to Buy Right Away With $4,000

Seeking strength from your investments? Then these are the three stocks to consider first.

Read more »

Investor wonders if it's safe to buy stocks now
Tech Stocks

Where Will BlackBerry Be in 4 Years?

With fresh partnerships and a tighter focus, BlackBerry is trying to lay the foundation for long-term growth.

Read more »

Start line on the highway
Tech Stocks

The Smartest Canadian Stock to Buy With $10,000 Right Now

Investors interested in tech can consider Constellation Software.

Read more »